Positions Related to Cell Senescence

Postdoctoral Research Associate in Bone Cell Senescence in Diabetes

Department of Biochemistry, South Parks Road, Oxford

Professor Lynne Cox’s lab is seeking to appoint a Postdoctoral Research Associate to investigate the role of senescent cells in bone fragility in type 1 diabetes, as part of a collaborative project between the University of Oxford, UK, and the Hadassah Medical Center, Jerusalem, Israel, under the 2019 BIRAX scheme.


This post will use molecular cell biology techniques to assess the presence and features of senescent cells from bone samples of diabetic mice, and under diabetic-mimicking conditions in vitro, to identify potential molecular targets for intervention. This project aims to identify possible drugs/agents for subsequent development as therapies to address the serious problem of bone fragility in ageing patients with type I diabetes.


This full-time fixed-term post is funded by BIRAX in partnership with Diabetes UK for up to 3 years in the first instance and is based at the Department of Biochemistry, South Parks Road, Oxford.


The closing date for applications is 12.00 noon on Monday 6 January 2020 with interviews for shortlisted candidates to be held as soon as possible thereafter.

Funded PhD Opportunity

Role of novel cardiac biomarkers in cellular senescence

Ulster University

Coronary Artery Disease (CAD) is the largest contributor to Cardiovascular Disease, and accounts for over a quarter of all deaths in Northern Ireland. Currently there is no definitive way to predict cardiac events. There is a crucial need therefore to develop better tests to predict those at risk of cardiovascular events for better disease management and ultimately to improve patient outcomes. In addition, little is known about molecular pathways impacted by many newly discovered cardiac biomarkers at NICSM, C-TRIC (These protiens are in the process of patent filing).

Recently, senescence was identified as the primary contributor to many age-associated diseases including CAD. We have undertaken a feasibility study on senescent proteins taking a multiplex proteomic approach in a prospective cohort of patients with CAD. Machine learning techniques were applied to the senescence related proteins identified, to yield predictive combinations that were able to accurately identify the CAD patients. A combination of just 3 senescence proteins was able to distinguish very high risk CAD patients from low risk with more than 90% accuracy. We cannot disclose names of these proteins due to intellectual property concerns, however, we want to urgently investigate their contribution to disease progression in cellular models. Not much is known about molecular pathways impacted by these senescence specific proteins.

The proposed project will manipulate these senescence proteins in two different models of senescence. We will perform RNA seq analysis on senescent cells with or without these biomarkers to uncover disease specific pathways impacted. Firstly, we will use our ER Ras senescence model system. ER Ras is an inducible senescence model, where we have engineered HRasG12V oncogene into IMR90 cells and these can be made senescent just by adding tamoxifen. Second model system to be utilized will the etoposide induced DNA damage model of senescence. Secondly, we will overexpress these biomarkers using standard models and investigate their contribution to the senescence program. We believe this could lead to discovery of innovative treatment options for CAD. The proposed 3-year project will be based at the Centre for Personalized Medicine (CPM) under the supervision of Dr Rai and Dr McGilligan research lecturers.

Researcher will be based at C-TRIC (Altnagelvin Hospital site).